Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies

Main Article Content

Lawrence Eichenfeld
University of California, San Diego, School of Medicine

Eric Simpson
Oregon Medical Research Center, Portland, OR, USA

Kim Papp
Probity Medical Research, Waterloo, ON, Canada

Jacek Szepietowski
Wroclaw Medical University, Wroclaw, Poland

Leon Kircik
Mount Sinai

Darryl Toth
XLR8 Medical Research and Probity Medical Research, Windsor, ON, Canada

Seth Forman
ForCare Clinical Research, Tampa, FL, USA

Michael Kuligowski
Incyte Corporation, Wilmington, DE, USA

May Venturanza
Incyte Corporation, Wilmington, DE, USA

Haobo Ren
Incyte Corporation, Wilmington, DE, USA

Amy Paller
Northwestern University Feinberg School of Medicine

Keywords

atopic dermatitis

Abstract

N/A

References

1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Silverberg NB, Durán-McKinster C. Dermatol Clin.
2017;35(3):351-363.

3. Bao L, et al. JAKSTAT. 2013;2(3):e24137.

4. Oetjen LK, et al. Cell. 2017;171(1):217-228.

5. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

6. Papp K, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. Presented at: Revolutionizing Atopic Dermatitis Conference, June 13, 2021

Article Sidebar

Poster PDF
Published
Mar 4, 2022
DOI https://doi.org/10.25251/skin.6.supp.28

Article Details

How to Cite
[1]
Eichenfeld, L., Simpson, E., Papp, K., Szepietowski, J., Kircik, L. , Toth, D., Forman, S., Kuligowski, M., Venturanza, M., Ren, H. and Paller, A. 2022. Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s28. DOI:https://doi.org/10.25251/skin.6.supp.28.
Issue
Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>